JOINT STOCK COMPANY
DANANG PHARMACEUTICAL – MEDICAL EQUIPMENT
No.: 97/TB-CT

"Explanation of changes in profit after corporate income tax in the Q4/2025 and FY2025 Financial Statements compared with the same period of the previous year"

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Da Nang, January 20, 2026

To: - State Securities Commission of Vietnam;
- Hanoi Stock Exchange.

1. Company name: Danang Pharmaceutical – Medical Equipment Joint Stock Company
2. Stock code: DDN (Upcom)
3. Head office: 02 Phan Dinh Phung, Hai Chau Ward, Danang City
4. Telephone: 0236.3822247 Fax: 0236.3891752

Published information content:

Pursuant to Circular No. 96/2020/TT-BTC dated November 16, 2020, Danang Pharmaceutical – Medical Equipment Joint Stock Company hereby provides the following explanation:

Profit after corporate income tax in the Q4/2025 and FY2025 Financial Statements changed by 10% or more compared to the same period of the previous year:

Indicator	Year 2025	Same period 2024	Difference (%)
Profit after CIT – Q4	2,013,983,395 đ	-2,927,999,402 đ	+ 168.8%
Profit after CIT – Full year	4,038,458,923 đ	7,624,152,377 đ	- 47.0%

Details:

* Profit after corporate income tax in Q4/2025 increased by 168.8% compared to Q4/2024, mainly because in 2024 the Company incurred significant expenses at the end of the year, whereas in 2025 such expenses were incurred evenly across the quarters.

* Profit after corporate income tax for FY2025 decreased by 47% compared to FY2024 because in 2024 the Company recognized income from the liquidation of unused accounts, while in 2025 the Company recorded losses from its investment in the NeoVita Vaccination Center and Medical Services system in Ho Chi Minh City.

Recipients:
- As above;
- Company website;
- Filed at Office.

GENERAL DIRECTOR

M.S.D.N: 0400101404 - C.T.C.P - CÔNG TY CỔ PHẦN DƯỢC - THIẾT BỊ Y TẾ ĐÀ NẴNG - THÀNH PHỐ ĐÀ NẴNG

NGUYEN LUONG TAM

Signature Not Verified
Ký bởi: CÔNG TY CỔ PHẦN DƯỢC - THIẾT BỊ Y TẾ ĐÀ NẴNG
Ký ngày: 20/1/2026 17:49:49